Seeking dogs with cancer to assess the safety and tolerability of a novel product designed to aid in the early detection of cancer

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Please answer a few questions to see if you may qualify.
Have questions? Please contact the study coordinator Oncology Clinical Trials Coordinators at or call (530) 754-1954
By clicking "Next", you're consenting to participate in this questionnaire. There are no right or wrong answers and everything you enter is secure.
  1. *1. What is your dog's name?
  2. *2. How much does your dog weigh?
  3. *3. Has your dog been diagnosed with advanced or metastatic cancer by a veterinarian?
  4. *4. How did you hear about this study?
  5. *5. Please provide a short summary of what is going on with your dog.
Logo Image
"Help us improve the early detection of cancer in dogs!"
Animal: Dogs
Healthy Pets: No
Keywords: cancer, oncology
Type: pharmacodynamic
18 Participants
Background and purpose
Detecting natural cancer biomarkers in a blood sample is challenging due to the small amount of cancer DNA circulating in the bloodstream. The investigational drug in this trial, EARLI-001, is designed to make cancer cells produce synthetic biomarkers which could be more easily detected in a sample. This could lead to earlier and more effective cancer treatment.

The purpose of this trial is to determine the maximum tolerated dose and assess the safety of EARLI-001. Additionally, the trial will measure the amount of synthetic biomarkers produced by EARLI-001 that are present in the body (this is called pharmacodynamic or PD research).
What happens in this study

If the exams, tests, and procedures show that your pet can take part in the study, and you choose to enroll them, you pet will attend a total of five study visits. At the enrollment visit (Day 1), your pet will have a physical examination and blood collected for complete blood count (CBC), chemistry panel, and study purposes. Your pet will receive an intravenous dose of EARLI-001 and be monitored for two hours. At the follow-up visits (Days 4, 8, 12, and 15) your pet will have a physical examination and blood collected for complete blood count (CBC), chemistry panel, and/or study purposes.

Pet owner responsibilities

If you wish to have your pet participate in this study, you will be responsible for bringing your pet for each study visit.

Participation requirements

We are looking for dogs with confirmed locally advanced or metastatic cancer who have not undergone treatment within the past 30 days.

Benefits and risks of participating
Possible benefits include helping to advance early detection of cancer. The information from this study may benefit future cancer populations (not only animals but also people).

EARLI-001 has been tested in dogs previously. No significant adverse events were reported in doses at the same levels being looked at in this study. A decrease in serum glucose levels was noted in one dog and this resolved on its own. At doses three times higher than what is being given in this study symptoms of listlessness, salivation, lethargy, vomiting, and tremors were reported. These symptoms resolved within a few days.

In addition to these risks, this study may affect your dog in ways that are unknown. These may be a minor inconvenience or may be so severe as to cause death.
The study will contribute up to $2000.00 towards the costs of your dog’s care at the VMTH if your dog completes the study.
Study duration and period
You pet will attend 5 study visits over the course of two weeks.
Recruitment period
From Sept. 1, 2020 to Aug. 1, 2021
UC Davis Veterinary Medical Teaching Hospital
1 Garrod Drive
Davis, CA 95616
Oncology Clinical Trials Coordinators
Research Topic
  • cancer

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview